In recent years, the checkpoint inhibitors targeted programmed cell death 1 (PD-1) and its ligand 1 (PD-1 ligand, PD-L1) achieved landmark significance in treating a variety of cancers including non-small cell lung cancer (NSCLC). However, current immunotherapy is not precise enough, only 15%-20% of the unselected patients can benefit from the therapy, and there is a possibility of hyperprogression (HP). Therefore, how to select the dominant population is crucial. Although many studies have emphasized the importance of PD-L1 and tumor mutation burden (TMB) and other indicators to guide immunotherapy, current PD-L1 expression level and mutation load cannot be used as a decisive and excluded predictive marker based on various obstacles. With the deepening of research, we found that there is a close relationship between lung cancer-driver gene mutation and aberrant activation of PD-1/PD-L1 signal pathways, and the correlation between gene mutation and immunotherapy efficacy has broad research value. This article will revolve around the above issues. .
【中文题目：非小细胞肺癌中驱动基因状态与免疫治疗 相关性的研究进展】 【中文摘要：近几年，针对阻断程序性死亡蛋白1（programmed cell death 1, PD-1）及其配体1（PD-1 ligand, PD-L1）的免疫检查点抑制剂在非小细胞肺癌（non-small cell lung cancer, NSCLC）治疗中取得了里程碑式的意义。然而目前的免疫治疗还不够精准，在未经选择人群中有效率偏低，只有15%-20%患者能从中获益，且有发生超进展（hyperprogression, HP）的几率。因此，如何选择优势人群至关重要。虽然很多研究强调了肿瘤细胞表面PD-L1表达水平及肿瘤突变负荷（tumor mutation burden, TMB）检测等指标指导免疫治疗的重要性，然而基于各种障碍，目前PD-L1表达水平及TMB尚不能作为决定性、排除性的预测标志物。随着研究深入，我们发现肺癌驱动基因突变与PD-1/PD-L1信号的异常激活之间有着密切的联系，基因突变与免疫治疗疗效的相关性尚有广阔研究价值。本文就基因突变预测免疫检查点抑制剂疗效及HP可能的研究进展作一综述。 】 【中文关键词：肺肿瘤；免疫治疗；驱动基因；超进展】.
Keywords: Driver Gene; Hyperprogression; Immnotherapy; Lung neoplasms.